Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

1.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex
A number of financial firms and investment banks 
Via Benzinga
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: 
Via Benzinga
Palo Santo: New Venture Capital Group Raises $35M To Focus On Psychedelic Medicine
Palo Santo, a newly-created venture capital fund with an eye on psychedelic medicines, announced its official launch on Thursday. 
Via Benzinga
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing... 
Via Talk Markets
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech
It's off to a running start. 
Via The Motley Fool
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Opening Day: WalkMe Stock Price Falls Following $287M IPO
Backed by Insight Venture Partners, WalkMe fell as much as 7% in its trading debut earlier this week after a $287M initial public offering. According to filings, Insight will remain WalkMe's biggest... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
58 Biggest Movers From Friday
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Is ATAI Stock A Buy After The IPO?
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. 
Via Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offer... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.